Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Gastric bypass for diabetic patients <35 BMI
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Cerebrovascular Disease, Mild Cognitive Impairment
Interventions
Heart Health Intervention
Behavioral
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
55 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Inflammation, Inflammatory Response
Interventions
Marine Lipid Oil Concentrate, Dietary Supplement, Placebo
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Conditions
HIV Infections
Interventions
Testosterone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 16 more
Conditions
Endometrial Hyperplasia, Grade 1 Endometrial Cancer
Interventions
Telemedicine behavioral weight intervention, Progestin, Enhanced usual care, Levonorgestrel-releasing IUD.
Behavioral · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
St Louis, Missouri • Albuquerque, New Mexico • Oklahoma City, Oklahoma
Conditions
Adenocarcinoma of the Endometrium
Interventions
Metformin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Obesity, Weight Loss, Delayed Gastric Emptying Following Procedure, Obesity, Mild, Obesity, Morbid, Obesity; Excess Calories
Interventions
Bariatric Endoscopic Antral Myotomy
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions
Medical Device Usage and Evaluation, Tirzepatide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Chicago, Illinois • Houston, Texas
Completed Not applicable Interventional

Cryoablation for Obesity Management

NCT03092778
Conditions
Obesity
Interventions
Cryoablation
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Conditions
Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma
Interventions
Tirzepatide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Mild Cognitive Impairment, Obesity
Interventions
Time restricted eating
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Obesity, Mild
Interventions
TENS Active Treatment, Sham Device
Device
Lead sponsor
Elira, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Scottsdale, Arizona • Santa Monica, California • Miami, Florida + 2 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)

NCT07180147
Conditions
Alzheimer Disease (AD), Cardio Vascular Disease, Mild Cognitive Impairment (MCI), Frailty Syndrome, Disability Physical, Hypertension, Metabolic Syndrome (MetS), Healthy Aging, Obesity &Amp; Overweight
Interventions
Not listed
Lead sponsor
Marymount University
Other
Eligibility
50 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Arlington, Virginia
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Idiopathic Intracranial Hypertension Treatment Trial

NCT01003639
Conditions
Idiopathic Intracranial Hypertension
Interventions
Acetazolamide, Placebo, Formal weight loss counselling program
Drug · Behavioral
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Waterbury, Connecticut + 31 more
Conditions
Oxidized Low Density Lipoprotein
Interventions
Cardio formulation, Placebo
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Conditions
Obesity, Heart Failure
Interventions
NNC0487-0111, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
5,610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
206
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 173 more
Conditions
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
5,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
111
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 99 more
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Laparoscopic sleeve gastrectomy, Intensive medical management
Procedure · Behavioral
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 4 Interventional Results available

Genomic Outcomes of Metformin

NCT02986659
Conditions
Coronary Artery Disease, Mild Cognitive Impairment, Obesity, Abdominal, Hypertension
Interventions
Metformin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina